Immuneel Therapeutics has made a groundbreaking advancement in cancer treatment with the launch of Qartemi, India’s first global CAR T-cell therapy specifically designed for adult patients with B-cell non-Hodgkin lymphoma (B-NHL). This innovative therapy addresses a critical need in India’s healthcare system, particularly as the country grapples with a rising incidence of blood cancers, which sees approximately 120,000 new cases and over 70,000 deaths annually from conditions like leukemia and lymphoma.
A New Hope for Patients
Qartemi represents a significant leap forward in personalized medicine, offering a tailored approach for individuals whose conventional treatments have failed. Kiran Mazumdar-Shaw, co-founder and board director of Immuneel Therapeutics, emphasized the company’s mission since its inception in 2019: to provide affordable and life-saving therapies that are often inaccessible to many patients. With Qartemi, Immuneel aims to transform cancer care in India by making advanced treatments available at a fraction of the cost compared to international alternatives.
Clinical Trials and Efficacy
The development of Qartemi was supported by the IMAGINE Phase 2 trial, which began in 2022 and involved multiple leading hospitals across India. The trial demonstrated promising results, achieving an impressive overall response rate (ORR) of 83.3% at Day+90. This level of efficacy aligns closely with CAR T-cell therapies that have received approval from the U.S. Food and Drug Administration (FDA), establishing Qartemi as a competitive option on the global stage.
Collaboration and Accessibility
Immuneel has partnered with numerous esteemed hospitals, including Narayana Health, Apollo Hospitals, and CMC Vellore, to ensure that Qartemi is accessible to patients across India. This collaboration is crucial for delivering cutting-edge therapies to those who need them most, particularly when traditional treatments fall short.
The Future of Cancer Treatment in India
As Immuneel continues to innovate within the field of cell and gene therapy, their commitment to affordability and accessibility remains at the forefront. Amit Mookim, CEO of Immuneel Therapeutics, highlighted that for the first time, Indian patients can look forward to lasting remission from relapsed and refractory non-Hodgkin lymphoma. This breakthrough not only provides hope but also positions India as a leader in next-generation cancer therapies.
In summary, the launch of Qartemi marks a transformative moment in India’s fight against cancer. By harnessing the power of CAR T-cell therapy and making it accessible at an affordable price, Immuneel Therapeutics is paving the way for improved patient outcomes and redefining what is possible in cancer treatment.
Also Read – New Way to Find Ulcer and Stomach Cancer-Causing Bacteria
